The audio industry is full of hype with the most nonsense surrounding the simplest component of the A/V chain - interconnects and speaker cables. Because there are often very little measurable and audible differences between cables, many of the exotic cable vendors use psuedo junk science to differentiate their products from their competitors. These vendors often prey upon the suggestible audiophile giving them reasons why these products must be utilized in their precious systems in order to achieve the best performance possible to reach the true path of audio nirvana. Listed below are the top 10 cable snake oil claims to watch out for. If a vendor is selling you on any of these fallacies, run don't walk away from their products, unless of course you enjoy a good sci-fi story and desire to buy expensive audio jewelery.
Links from or to websites, including links to the Websites, are for convenience only. The RBC Companies do not review or control, and are not responsible for, any websites linked from or to the Websites, the content of those websites, the privacy practices of those websites, the third parties named therein, or their products or services. Linking to any other website is at your sole risk and the RBC Companies will not be responsible or liable for any damages in connection with such linking. In addition, the RBC Companies do not endorse or approve of any websites linked from or to the Websites, except for Websites of RBC Companies.
Eli Lilly ($LLY) has two Humulin R products: U-100 and U-500, the latter of which is 5 times more concentrated. The more potent form is advised for Type 2 diabetes sufferers who have developed insulin resistance to the point that they are injecting more than 200 units of it per day. The concentrated U-500 allows them to inject smaller amounts, and in some cases take fewer injections a day. But because it is concentrated, it is more dangerous, and overdose errors have been an issue, according to the Institute for Safe Medication Practices, as patients struggle with conversions with their syringes. A Lilly spokeswoman said the company is developing both a Humulin R U-500 insulin delivery device and dedicated syringe but can't speculate as to how soon it will be done and approved: "These dedicated devices, if approved, will allow administration of Humulin R U-500 in actual units without dose conversion to non-dedicated syringe unit markings." -- Eric Palmer (email | Twitter )